This drug works so well for weight loss that celebrities and influencers are all trying to get their hands on it.
Headlines for a healthier you | | Using Diabetes Drugs for Weight Loss | | Hollywood's latest weight loss fad? A type 2 diabetes drug named Ozempic. Its active ingredient, semaglutide, can help lower blood sugar level. It can also suppress appetite, making people feel less hungry. This drug works so well for weight loss that celebrities and influencers are all trying to get their hands on it. The craze has contributed to a national drug shortage, which hurts diabetes patients who have real needs for these medications. | Know More | Despite misleading claims on TikTok, Ozempic is only FDA-approved to treat type 2 diabetes currently. Wegovy, another drug that contains semaglutide, is approved for chronic weight management in people with obesity. Once patients stop using Wegovy, they're likely to see weight gain again. | Feel Better | Novo Nordisk, the company that makes Ozempic and Wegovy, is working to resolve the drug shortage. In the meantime, some experts have urged healthcare providers to prioritize diabetes patients for prescriptions. | | | | What Else Should You Know | | More Variants Are Emerging | Several Omicron subvariants, including BQ.1.1 and BQ.1, are slowly growing in prevalence. These new variants appear to render monoclonal antibody treatments ineffective. But experts say the new bivalent booster should still protect against these variants. | | | | | You Can Now Access Your Health Records Digitally | Under new federal rules, you now have the right as a patient to request electronic medical records from your healthcare provider. Being able to access your test results and medication history will give you more control over your health decisions. Read more to learn about how you can go about requesting your digital health records. | | | | | | In Other News | | - If You Really Want to Be Happy, Spend More Time With Strangers. The Guardian
- For Disabled Workers, a Tight Labor Market Opens New Doors. The New York Times
| | | |
No comments:
Post a Comment